EPI2ME Labs 22.05.01 Release

By Stephen Rudd
Published in Software Releases
May 04, 2022
2 min read

Dear Nanopore Community,

We are pleased to release a new version of the EPI2ME Labs software that introduces an updated and simplified user experience. EPI2ME Labs is now a standalone application that continues to provide a clean interface to accessing bioinformatics workflows and tutorials for the analysis of nanopore sequence data. This release also brings our workflow capabilities to users working from Windows computers.

Figure 1. The new version of EPI2ME Labs has an updated and simplified graphical interface. The software brings our workflow capabilities to our Windows users and the analytical focus is now targeted towards the bioinformatics workflows.

There are a number of key changes within the updated EPI2ME Labs software that are summarised below:

The EPI2ME Labs Launcher software has been deprecated - the new EPI2ME Labs software automatically orchestrates the download, start and stop of the required Docker containers. The EPI2ME Labs software functions as a standalone application and now delivers the Jupyter interface itself. The EPI2ME Labs software is focusing on our collection of Nextflow based workflows. These have been improved with additional in-application documentation to better describe the workflows, their parameters, and configuration. Updates to the workflow integration make it simpler to re-run workflows that have been pre-configured with preferred parameters, databases, or reference genomes. The command-line access to the software has been maintained and for advanced users, the ability to start multiple sessions on a server remains possible. The installer software has been updated to simplify the installation for Windows users - the installer scripts now orchestrate the installation of most dependencies (WSL2, an Ubuntu VM, Nextflow and its Java dependencies). The only unmanaged software dependency is now Docker, which can be downloaded as Docker Desktop.

Figure 2. The workflow functionality in EPI2ME Labs has been enriched and additional run metadata and logging is now presented. The "Rerun workflow" button shown in the screenshot allows an analysis to be re-run; preferred parameters and e.g. reference genomes are copied. This encourages reproducibility and simplifies the analysis of data from larger studies.

The EPI2ME Labs software is available from our Downloads page. Additional information is provided in the project’s CHANGELOG.

It is recommended that a previous installation of the EPI2ME Labs Launcher is first removed - the new EPI2ME Labs software cannot uninstall the now deprecated EPI2ME Labs Launcher software.

New workflow releases

The EPI2ME Labs release also includes updates to some of our workflows. The template for our Nextflow based workflows can be found at wf-template.

Notably wf-tb-amr has been updated to version v1.0.0. This version now uses the bcftools mpileup software for variant calling and uses a larger collection of WHO defined variants in antibiotic resistance association. Please see the changelog for additional information on the changes. wf-metagenomics has been updated to version v1.1.3. This update includes in-application documentation improvements required for functionality with the EPI2ME Labs software.

We look forwards to any feedback and would welcome recommendations for new workflows, tutorials, and features.


Stephen Rudd

Stephen Rudd

Bioinformatics product manager

Related Posts

EPI2ME Labs 22.12.01 Release
December 07, 2022
1 min

Quick Links

TutorialsWorkflowsOpen DataContact

Social Media

© 2020 - 2022 Oxford Nanopore Technologies plc. All rights reserved. Registered Office: Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK | Registered No. 05386273 | VAT No 336942382. Oxford Nanopore Technologies, the Wheel icon, EPI2ME, Flongle, GridION, Metrichor, MinION, MinIT, MinKNOW, Plongle, PromethION, SmidgION, Ubik and VolTRAX are registered trademarks of Oxford Nanopore Technologies plc in various countries. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.